Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy (ITN057AD)

Trial Profile

Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy (ITN057AD)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Tezepelumab (Primary) ; Immunotherapies
  • Indications Hypersensitivity
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Mar 2017 Planned End Date changed from 1 Sep 2018 to 26 Feb 2019.
    • 17 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 26 Feb 2019.
    • 17 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top